Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.40 |
| ▸ | INSR | P06213 | 4/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25296774 | 0.87 | MAP4K1 (0.51) | EGFRALKMAP4K1BTKCDK19 | |
| SCHEMBL29208841 | 0.83 | EGFR (0.54) | EGFRALKBTKCDK19 | |
| SCHEMBL25001385 | 0.83 | EGFR (0.60) | EGFRALKMAP4K1INSRBTK | |
| SCHEMBL29208829 | 0.82 | ALK (0.61) | ALKINSR | |
| SCHEMBL25303779 | 0.80 | EGFR (0.58) | EGFRALKMAP4K1INSRBTK | |
| SCHEMBL29208769 | 0.80 | ULK1 (0.56) | EGFRALKMAP4K1INSRBTK | |
| SCHEMBL29208821 | 0.79 | EGFR (0.47) | EGFRALKBTKTTK | |
| SCHEMBL25001806 | 0.79 | EGFR (0.49) | EGFRALKMAP4K1BTK | |
| SCHEMBL25001697 | 0.78 | EGFR (0.52) | EGFRALKMAP4K1BTKTTK | |
| SCHEMBL25001448 | 0.78 | EGFR (0.58) | EGFRALKMAP4K1INSRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 16/4885MAP4K1 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.